During the 2017-2018 flu epidemic, the point-of-care Alere-i (n = 72) and reverse transcription polymerase chain reaction (n = 106) tests were compared. Patients in the point-of-care group were administered oseltamivir significantly more rapidly (9 hours vs 23 hours), they spent less time in the emergency department, and they had lower rates of antibiotic administration and hospitalization.
Keywords: influenza; nucleic-acid amplification test; oseltamivir; point of care; seasonal flu.
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.